Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for Benign Prostatic Hyperplasia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Benign Prostatic Hyperplasia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on Benign Prostatic Hyperplasia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for benignprostatichyperplasia 1 Driving better decision-making in healthcare Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benignprostatichyperplasia Technology Guidance from the MOH Drug Advisory Committee Update published on 1 April 2020 Guidance Recommendations The Ministry of Health’s Drug Advisory Committee has recommended: ? Alfuzosin 10 mg tablet and dutasteride 0.5 mg (...) capsule for treating benignprostatichyperplasia. Subsidy status Alfuzosin 10 mg tablet and dutasteride 0.5 mg capsule are recommended for inclusion on the MOH Standard Drug List (SDL). SDL subsidy does not apply to tamsulosin 0.4 mg tablet or dutasteride 0.5 mg/tamsulosin 0.4 mg capsule. 2 Driving better decision-making in healthcare Factors considered to inform the recommendations for subsidy Technology evaluation 1.1 1.2 1.3 1.4 The MOH Drug Advisory Committee (“the Committee”) considered
Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benignprostatichyperplasia. New minimal invasive surgeries have been suggested as alternative options to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benignprostatichyperplasia (BPH). Convective radiofrequency water vapour thermal therapy is a new technology that uses targeted, controlled water vapour energy (steam (...) ) to create necrotic tissue in the prostate.To assess the effects of convective radiofrequency water vapour thermal therapy for the treatment of lower urinary tract symptoms in men with benignprostatic hyperplasia.We performed a comprehensive search of multiple databases (the Cochrane Library, MEDLINE, Embase, Latin American and the Caribbean Health Sciences Literature, Scopus, Web of Science), trials registries, other sources of grey literature, and conference proceedings published up to 18 February
Endoscopic non-contact (side-firing) visual laser ablation of the prostate (VLAP) for benignprostatichyperplasia (BPH) 1 Public Summary Document Application No. 1518 – Endoscopic visual laser ablation of the prostate (VLAP) for benignprostatichyperplasia Applicant: Boston Scientific Date of MSAC consideration: MSAC 75 th Meeting, 28-29 March 2019 Context for decision: MSAC makes its advice in accordance with its Terms of Reference, visit the MSAC website 1. Purpose of application (...) An application examining the evidence to support an increase in the Medicare Benefits Schedule (MBS) fee for endoscopic visual laser ablation of the prostate (VLAP), also known as photoselective vaporisation of the prostate [PVP] for men with benignprostatehyperplasia (BPH) was received from Boston Scientific Pty Ltd by the Department of Health. 2. MSAC’s advice to the Minister After considering the strength of the available evidence in relation to comparative safety, clinical effectiveness and cost
Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with BenignProstaticHyperplasia: A Review of Clinical Effectiveness Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with BenignProstaticHyperplasia: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Minimally-Invasive Treatments for Lower Urinary Tract Symptoms in People with BenignProstaticHyperplasia: A Review of Clinical Effectiveness Minimally-Invasive Treatments (...) for Lower Urinary Tract Symptoms in People with BenignProstaticHyperplasia: A Review of Clinical Effectiveness Last updated: August 29, 2019 Project Number: RC1172-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of select minimally-invasive treatments for the management of lower urinary tract symptoms in people with benignprostatichyperplasia? Key Message Four recent systematic reviews
BenignProstaticHyperplasia: Surgical Management of BenignProstaticHyperplasia/Lower Urinary Tract Symptoms BenignProstaticHyperplasia (BPH) Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors (...) Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education BenignProstaticHyperplasia: Surgical Management of BenignProstaticHyperplasia/Lower Urinary Tract Symptoms (2018, amended 2019) Published 2018, Amended 2019 The goal of this revised guideline is to provide a useful reference on the effective evidence-based surgical management of male lower urinary tract symptoms secondary to benignprostatic
Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benignprostatichyperplasia. A variety of minimally invasive surgical approaches are available as an alternative to transurethral resection of prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benignprostatichyperplasia (BPH). A recent addition to these is prostatic urethral lift (PUL).To assess the effects of PUL for the treatment of LUTS in men with BPH.We performed (...) not find any non-RCTs.Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted them according to the Cochrane Handbook for Systematic Reviews of Interventions. We planned subgroup analyses by age, prostate volume, and severity of baseline symptoms. We used the GRADE approach to rate the certainty of the evidence.We included two RCTs with 297 participants comparing PUL to sham
2019CochraneControlled trial quality: predicted high
Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to BenignProstaticHyperplasia Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to BenignProstaticHyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological (...) Attributed to BenignProstaticHyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Société Française de Radiologie, and the British Society of Interventional Radiology Endorsed by the Asia Pacific Society of Cardiovascular and Interventional Radiology, Canadian Association for Interventional Radiology, Chinese College of Interventionalists, Interventional Radiology Society of Australasia, Japanese Society of Interventional
Lower Urinary Tract Symptoms-Suspicion of BenignProstaticHyperplasia Date of origin: 1995 Last review date: 2014 ACR Appropriateness Criteria ® 1 Lower Urinary Tract Symptoms: Suspicion of BPH American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Lower Urinary Tract Symptoms: Suspicion of BenignProstaticHyperplasia Radiologic Procedure Rating Comments RRL* US pelvis (bladder and prostate) transabdominal 6 Consider this procedure after patient voids to measure (...) without IV contrast 1 ???? CT abdomen and pelvis with IV contrast 1 ???? Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Lower Urinary Tract Symptoms: Suspicion of BPH LOWER URINARY TRACT SYMPTOMS: SUSPICION OF BENIGNPROSTATICHYPERPLASIA Expert Panel on Urologic Imaging: Barak Friedman, MD 1 ; John R. Leyendecker, MD 2 ; M. Donald Blaufox, MD, PhD 3 ; Steven C. Eberhardt, MD 4 ; Pat F. Fulgham
Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benignprostatichyperplasia. New, minimally invasive surgeries have emerged as alternatives to transurethral resection of the prostate (TURP) for the management of lower urinary tract symptoms (LUTS) in men with benignprostatichyperplasia (BPH). Aquablation is a novel, minimally invasive, water-based therapy, combining image guidance and robotics for the removal of prostatic tissue.To assess the effects (...) of Aquablation for the treatment of lower urinary tract symptoms in men with benignprostatic hyperplasia.We performed a comprehensive search using multiple databases (the Cochrane Library, MEDLINE, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to 11 February 2019, with no restrictions on the language or status of publication.We included parallel-group randomised controlled trials (RCTs) and cluster-RCTs, as well
Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benignprostatichyperplasia. 29938670 2018 12 11 2018 12 11 1024-2708 23 Suppl 2 3 2017 06 Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Effect of weight reduction on severity of lower urinary tract symptoms in obese men with benignprostatichyperplasia. 35-37 Ng C F CF Division of Urology, Department of Surgery, The Chinese University of Hong Kong. Yee C H CH Division of Urology (...) Urinary Tract Symptoms drug therapy Male Middle Aged Obesity Prospective Studies ProstaticHyperplasia drug therapy Severity of Illness Index Weight Loss 2018 6 26 6 0 2018 6 26 6 0 2018 12 12 6 0 ppublish 29938670
BenignprostatichyperplasiaBenignprostatichyperplasia - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search Benignprostatichyperplasia Last reviewed: February 2019 Last updated: September 2018 Summary Multi-factorial involving smooth muscle hyperplasia, prostatic enlargement, and bladder dysfunction, as well as input from the central nervous system. Presents with both storage symptoms (frequency, urgency, nocturia (...) invasive therapy. Failure of medical management or renal complications are indications for surgical intervention. There are a host of procedural treatments, which have unique risk/benefit profiles for consideration. Definition Lower urinary tract symptoms (LUTS) caused by bladder outlet obstruction due to benignprostatichyperplasia (BPH), also known as benignprostatic enlargement (BPE), are predominantly due to 2 components: a static component related to an increase in benignprostatic tissue
Rezum for treating benignprostatichyperplasia Rezum for treating benignprostatic h Rezum for treating benignprostatichyperplasia yperplasia Medtech innovation briefing Published: 24 August 2018 nice.org.uk/guidance/mib158 pathways Summary Summary The technology technology described in this briefing is Rezum, which uses steam to ablate prostate tissue with the aim of improving lower urinary tract symptoms secondary to benignprostatichyperplasia. The inno innovativ vative aspects e aspects (...) are that the company claims that it is quicker to do than existing treatments and can be done as a day case. The intended place in ther place in therap apy y would be as an alternative to current standard care in people with lower urinary tract symptoms presumed to be secondary to benignprostatichyperplasia. The main points from the e main points from the evidence vidence summarised in this briefing are from 4 studies (blinded control trial, 1 single-arm pilot study and 2 retrospective observational studies
Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benignprostatichyperplasia: randomised, open label, non-inferiority trial. To compare prostatic artery embolisation (PAE) with transurethral resection of the prostate (TURP) in the treatment of lower urinary tract symptoms secondary to benignprostatichyperplasia in terms of patient reported and functional outcomes.Randomised, open label, non-inferiority trial.Urology and radiology (...) departments of a Swiss tertiary care centre.103 patients aged ≥40 years with refractory lower urinary tract symptoms secondary to benignprostatichyperplasia were randomised between 11 February 2014 and 24 May 2017; 48 and 51 patients reached the primary endpoint 12 weeks after PAE and TURP, respectively.PAE performed with 250-400 μm microspheres under local anaesthesia versus monopolar TURP performed under spinal or general anaesthesia.Primary outcome was change in international prostate symptoms score